Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of rozanolixizumab in generalized myasthenia gravis
2019-000969-21Phase 3Completed
- Sponsor
- UCB
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rozanolixizumab in myasthenia gravis (MG), sponsored by UCB. Primary endpoint: Treatment-emergent adverse events. Started Oct 2019; status: completed.
02
Drugs
rozanolixizumab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2019-000969-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000969-21.